Bionest

The Rise of the Chief Digital Officer in Pharma Companies

Chief Digital Officer (CDO) is the latest title to become a standard within the pharmaceutical company C-suite, with Takeda, Bayer, GlaxoSmithKline, Novartis, Merck, Sanofi and others all making such appointments in recent years. As we’ve written before, this addition to the pharma senior management team reflects the growing importance of digital to pharma, which encompasses...

Bionest

Machine Learning and Drug R&D

We recently wrote about the growing use of machine learning and artificial intelligence (AI) in healthcare. That blog post talked primarily about the expanding applications of AI in clinical diagnostics, based on AI’s superior abilities in pattern recognition. Within the pharmaceutical industry, however, machine learning technologies hold the most potential for revolutionizing drug discovery and...

Bionest

Differentiation Through Digital  

Digital technology is becoming increasingly important in the healthcare space. This was clearly reflected by the growing number of companies and events focused on the digital healthcare sector during JP Morgan/Biotech Week in San Francisco and new conferences dedicated to digital technology applications in health and wellness that have been scheduled for 2019. Uses of...

Bionest

Biotech Companies Flock to Newly Liberalized Hong Kong Stock Exchange

The Stock Exchange of Hong Kong Limited (The Exchange) adopted new rules on April 30 that for the first time enable pre-revenue companies in “emerging and innovative sectors” — including biotechnology — to submit formal applications to list on that exchange. This was the outcome of a careful four-year process aimed at making the Exchange...

Bionest

The Rise of AI in Drug Discovery and Development

“Deep learning” is an advanced machine learning technology that enables the generation of relevant insights from enormous amounts of data. Computers are able to identify complex patterns in data from many disparate sources and generate algorithms to explain them. This allows a computer to simultaneously create and test original hypotheses with much greater speed and...

Bionest

RNA Interference Achieves Key Milestone with Patisiran Success

It is a not uncommon phenomenon for a new discovery to attract much enthusiasm and hype — as well as investment and new company formation — only to suffer popular disillusionment a few years later as public interest turns to the next hot area of science when clinical success remains elusive and far off. After...

Bionest

ESMO 2017 — Part 2: Building on Biomarkers

The news from ESMO in September once again has highlighted the utility and need for biomarkers to help determine not only who will likely benefit from a particular immuno-oncology (IO) treatment, but also who may require a combination of such therapies right from the start.   While higher levels of PD-L1 have generally correlated with...

Bionest

New Big Data Initiatives in Oncology

As cancer therapy moves towards the concept of “real-time” oncology — the ability to constantly monitor changes in a patient’s disease and adjust treatment accordingly — we see big data and high powered analytical approaches increasingly playing a key role. The aim of such efforts will be to find novel biomarkers and a new understanding...

Bionest

Advances and Set Backs for CAR-T Therapy

Late August and early September was a period of big news — both positive and negative — on the CAR-T front. On the positive side, Novartis’ received the first FDA approval of a CAR-T therapy for Kymriah (tisagenlecleucel), for the treatment of children and young adults with B-cell precursor acute lymphoblastic leukemia that is refractory...